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1. Abstract 1 
The endocannabinoid (eCB) and serotonin (5-HT) systems have key roles in the regulation of 2 
several physiological functions like motor activity and food intake but also in the 3 
development of psychiatric disorders. Here we tested the hypothesis, whether blockade of 4 
serotonin 2C (5-HT2C) receptors prevents the reduced locomotor activity and other behavioral 5 
effects caused by a cannabinoid 1 (CB1) receptor antagonist. As a pretreatment, we 6 
administered SB-242084 (1 mg/kg, ip.), a 5-HT2C receptor antagonist or vehicle (VEH) 7 
followed by the treatment with AM-251 (5 or 10 mg/kg, ip.), a CB1 receptor antagonist or 8 
VEH. The effects of the two drugs alone or in co-administration were investigated in social 9 
interaction (SI) and elevated plus maze (EPM) tests in male Wistar rats. Our results show that 10 
AM-251 decreased the time spent with rearing in the SI test and decreased locomotor activity 11 
in EPM test. In contrast, SB-242084 produced increased locomotor activity in SI test and 12 
evoked anxiolytic-like effect in both SI and EPM tests. When applied the drugs in 13 
combination, these behavioral effects of AM-251 were moderated by SB-242084. Based on 14 
these findings we conclude that certain unwanted behavioral effects of CB1 receptor 15 
antagonists could be prevented by pretreatment with 5-HT2C receptor antagonists.  16 
2. Introduction 17 
The potential therapeutic modulation of the endocannabinoid (eCB) system and the role of 18 
cannabinoid 1 (CB1) receptors in the regulation of various physiological functions have been 19 
extensively investigated in the past decade. The most promising CB1 receptor antagonist 20 
drugs had been developed for the therapy of obesity and metabolic syndrome, however, these 21 
drugs have been suspended due to their psychiatric side effects, such as depressive-like 22 
symptoms, psychomotor retardation and anxiety [1]. Exploration of the eCB system is still in 23 
the focus of medical research, so, understanding the mechanism of the side effects caused by 24 
CB1 receptor antagonists is sufficient to work out interventions to prevent them, which may 25 
open a way for new therapeutic application of these drugs. Regarding the development of 26 
psychiatric side effects of CB1 receptor antagonists, animal studies have shown that activation 27 
or blockade of CB1 receptors modulate the excitability of serotonergic neurons in dorsal raphe 28 
nucleus and influences the serotonin release [2]. Furthermore, a growing body of human 29 
studies suggests that serotonergic neurons appreciably contribute to the development of 30 
psychiatric side effects induced by CB1 receptor antagonists [3]. At the same time, the key 31 
role of different 5-HT2 receptor subtypes has been demonstrated in the regulation of neuronal 32 
excitability, sleep-wake cycle and also in the control of anxiety and locomotor activity [4, 5]. 33 
The link between eCB system and locomotor regulation is shown by the fact that 34 
psychomotor performance of chronic cannabis smokers during abstinence is decreased [6], 35 
presumably as a result of the down regulation of CB1 receptors and eCB dysfunction in 36 
cortical areas and in basal ganglia [7, 8]. 37 
In terms of the interplay between the serotonergic and cannabinoid systems, it is important to 38 
emphasize, that the Gq/11 protein coupled 5-HT2C receptors and the Gi/Go-linked CB1 receptors 39 
are co-distributed in high density in brain regions related to mood and locomotor regulation 40 
together [9, 10]. The interaction between CB1 and 5-HT2C receptors has been demonstrated in 41 
the regulation of appetite too. Namely, administration of the CB1 receptor antagonist AM-251, 42 
either by microinjection into the nucleus accumbens or intraperitoneally, has been shown to 43 
produce hypophagia which effect was preventable with the 5-HT2C receptor antagonist SB-44 
242084 [11, 12]. However, interaction between these receptors has also been postulated in the 45 
control of other physiological processes, like movement and mood regulation [13, 14].  46 
Based on the above mentioned evidences, here we test the hypothesis if blockade of 5-HT2C 47 
receptors is able to prevent the reduced locomotor activity and anxiety-like effect caused by 48 
CB1 receptor antagonist, similarly to their interaction on food intake. For that, we injected the 49 
highly selective 5-HT2C receptor antagonist, SB 242084, as a pretreatment, before the 50 
application of AM-251 and tested the effect of the drugs using behavioral tests. We applied 51 
social interaction (SI) and elevated plus maze (EPM) tests, which apply psychological (social 52 
or environmental) stress factors, have remarkable locomotor component and were used most 53 
frequently to investigate the behavioral effects of AM-251 and SB-242084 [15].  54 
 55 
3. Materials and methods 56 
3.1. Animal maintenance 57 
All animal experiments and housing conditions were carried out in accordance with the EU 58 
Directive 2010/63/EU and the National Institutes of Health “Principles of Laboratory Animal 59 
Care” (NIH Publications No. 85-23, revised 1985), as well as specific national laws (the 60 
Hungarian Governmental Regulations on animal studies 40/2013). The experiments were 61 
approved by the National Scientific Ethical Committee on Animal Experimentation. Male, 62 
experimentally naïve, Wistar rats (220-320 g) were purchased from Animal Facility 63 
(Semmelweis University, Budapest, Hungary) and kept under controlled environmental 64 
conditions (temperature at 21±1°C, 12:12 light/dark cycle). We used different animals in the 65 
SI and EPM tests. Food and water were available ad libitum during the whole experiment. All 66 
effort was made to reduce pain and suffering of the animals.  67 
3.2. Drugs 68 
SB-242084 (SB) [ 6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] 69 
indoline] and AM-251 (AM) [ N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4- dichlorophenyl)-4-70 
methyl-1H-pyrazole-3-carboxamide] were purchased from Tocris Cookson ™ (Bristol, UK). 71 
Both compounds were dissolved in vehicle (VEH) consisted of 70% PBS (phosphate buffered 72 
saline, pH=7.4), 20% dimethylsulfoxide and 10% Tween 80. Animals were randomly 73 
assigned to the treatment groups. The applied doses of the drugs, namely 1 mg/kg for SB-74 
242084 and 5 or 10 mg/kg for AM-251 (AM D5 and AM D10, respectively) were chosen 75 
based on our previous experiments or publications demonstrating significant behavioral 76 
effects [16, 17]. All injections were performed intraperitoneally (ip.) in 1 ml/kg volume.  77 
3.3.  SI test 78 
The procedure was carried out as described earlier [18]. We established familiar conditions by 79 
creating a low-light (5 lx) and familiar arena to which rats were habituated for three days. 80 
Each rat was tested for social interaction with an unknown test partner with similar body 81 
weight (±15 g). Both members of a pair had the same prior familiarization experience and 82 
received the same drug treatment. At the end of the test, the box was wiped thoroughly and 83 
dried. The animals were tested in random order in a darkened room for 7.5 min, in the evenly 84 
illuminated test box (60 x 60 x 40 cm). All rats were treated with one of following treatments: 85 
VEH + VEH, VEH + AM D5, SB + VEH or SB + AM D5. The second injection was given 5 86 
min after the first one; the test was started 30 min after the second ip. injection. The behavior 87 
of the animals was recorded with a camcorder. Social interaction and locomotor activity were 88 
measured as previously described [18]. 89 
3.4.  EPM test  90 
The test was performed in the housing room of the rats, under artificial laboratory 91 
illumination (200 lx at maze level). The EPM apparatus (metal, painted black, arm length, 50 92 
cm; arm width, 15 cm; central platform, 15×15 cm; closed arm walls height, 40 cm) was 93 
elevated 50 cm above the floor. The test began by placing a single rat on the central platform 94 
facing an open arm. The first 5 min of free exploration were recorded with a camcorder. At 95 
the end of the test, the maze was cleaned thoroughly and dried. All rats were treated by one of 96 
the following treatments: VEH+VEH, VEH+AM D5, VEH+AM D10, SB+VEH, SB+AM D5 97 
or SB+AM D10. The second injection was given 10 min after the first one. The test was 98 
begun 30 min following the second treatment. Percentage of time spent in open arms (OAT 99 
%) and open/total (open plus closed) arm entries ratio (OAE %) were calculated and used as 100 
measures of anxiety. Closed arm entries (CAE) were considered as indicators of general 101 
locomotor activity.  102 
3.5.  Data analysis 103 
Camcorder recordings were stored and scored offline by an observer blind to the treatments, 104 
using Observer XT 10.0 software (Noldus®, The Netherlands). Data were analyzed with 105 
STATISTICA 7.0 (Statsoft®, Tulsa, USA). To evaluate the potential interactions between the 106 
drugs, two-way analysis of variance (ANOVA) was used with the following factors: (1) 107 
pretreatment: VEH or SB, (2) treatment: VEH, AM D5 or AM D10. To test the effect of 108 
different doses of drugs, one-way ANOVA was used followed by Dunnett’s post hoc analysis. 109 
Results are expressed as mean ± S.E.M. The results were considered statistically significant in 110 
case of p<0.05. 111 
4. Results 112 
4.1.  Effects of AM-251 and SB-242084 on explorative behavior in the SI, and locomotor 113 
activity in the SI and EPM tests 114 
In the SI test, we found a significant AM D5 effect in the rearing time and number (two-way 115 
ANOVA: F1,56=5.436, p=0.0233 and F1,56=6.418, p=0.0141, respectively). Post hoc result 116 
also showed, that AM D5 significantly reduced the rearing time (one-way ANOVA: 117 
F3,56=2.665, p=0.0565), presenting decline in explorative behavior. This effect was 118 
compensated, but not thoroughly blocked by SB pretreatment (for post hoc results see Fig. 1, 119 
A).  120 
As for line-crossing number, only SB showed significant effect in two-way ANOVA 121 
(F1,56=46.68, p<0.0001). Post hoc results showed, that SB caused a significant increase after 122 
VEH treatment, presenting elevated locomotor activity and this increase occured after AM D5 123 
treatment as well (one-way ANOVA: F3,44=6.928, p=0.0006; for post hoc analysis see Fig. 1, 124 
B) showing, that AM D5 treatment did not modulate the effect of SB in this parameter. 125 
In the EPM test, two-way ANOVA analysis showed significant effect of both SB and AM D5 126 
in the CAE parameter (F1,46=5.099, p=0.0287 and F1,46=4.243, p=0.0451, respectively). 127 
Regarding co-administration of SB and AM D10 in this parameter, significant SB effect and a 128 
trend in AM D10 effect were found in two-way ANOVA (F1,44=13.33, p=0.0007 and 129 
F1,44=3.124, p=0.0841, respectively), and a significant interaction effect as well (F1,44=5.624, 130 
p=0.0222). Thus, two-way ANOVA results presented, that both SB-242084 and AM-251 131 
modulated the locomotor activity in the EPM test. Regarding post hoc analysis, AM D5 and 132 
AM D10 treated groups showed a significant reduction in the CAE compared to the 133 
VEH+VEH treated group (F3, 44=6.928, p=0.0006, for post hoc analysis see Fig. 1, C). This 134 
effect of AM-251 on CAE was moderated by SB-242084 pretreatment in the co-treated 135 
groups (Fig. 1, C). 136 
 137 
4.2.  Effects of AM-251 and SB-242084 on mainly anxiety-related indices in SI and EPM 138 
tests 139 
In the SI test, both SB and AM D5 effects were seen in social interaction time parameter; two-140 
way ANOVA showed a significant SB effect and a tendency in AM D5 effect (F1,54=4.161, 141 
p=0.0463 and F1,54=2.817, p=0.0990, respectively). This pattern of effects were seen in the 142 
number of social interactions as well (two-way ANOVA: F1,54=10.12, p=0.0024 and 143 
F1,54=6.059, p=0.0171, respectively). Post hoc analysis also showed that SB treatment 144 
significantly increased the number of social interactions (one-way ANOVA: F3,54=5.777, 145 
p=0.0017, Fig. 2, B). Considering these measures of social interaction together, we can 146 
conclude that SB presented anxiolytic-like effect. AM D5 did not cause significant 147 
anxiogenic-like effect on its own in these parameters, but evoked its effect after SB 148 
pretreatment (Fig. 2, B). These results presented that both SB-242084 and AM-251 have 149 
effect on anxiety-related social behaviors in co-treated group. 150 
Regarding the non-social, but anxiety-related self-grooming behavior, both SB and AM D5 151 
treatment revealed significant effect (two-way ANOVA: F1,53=7.745, p=0.0074 and 152 
F1,53=5.559, p=0.0221, respectively) in the time spent with self-grooming measure (Fig. 2, C). 153 
However, in the number of self-grooming, only AM D5 had significant effect (two-way 154 
ANOVA: F1,55=10.53, p=0.0020), (Fig. 2, D). 155 
In the EPM test, in the SB and AM D5 combination, two-way ANOVA showed a significant 156 
effect of SB in absolute indices, like OAT (F1,44=15.30, p=0.0003) and OAE (F1,46=16.61, 157 
p=0.0002), and in calculated indices, like OAT% (F1,44=16.22, p=0.0002), OAE% 158 
(F1,47=6.777, p=0.0123). Co-administration of SB with AM D10 also showed a significant 159 
effect of SB in two-way ANOVA statistics: OAT (F1,44=22.44, p<0.0001), OAE (F1,45=23.45, 160 
p<0.0001), OAT% (F1,43=19.96, p<0.0001), OAE % (F1,47=7.645, p=0.0081). Significant 161 
AM-251 or interaction effects were not observed in the anxiety-related parameters in the EPM 162 
test. 163 
Based on one-way ANOVA statistics and post hoc analysis, SB significantly increased the 164 
OAT% (F5,66=6.097, p<0.001), the OAE (F5,68=6.053, p<0.001) as well as the OAE% 165 
(F5,68=2.684, p<0.05) indices showing clear anxiolytic-like effect (for post hoc results see Fig. 166 
3). AM D5 and AM D10 caused no difference in the anxiety-related EPM indices compared 167 
to the VEH + VEH treated group based on post hoc results (Fig. 3.). At the same time, in the 168 
co-treated groups, anxiolytic-like effect of SB in some cases was mildly modulated by AM-169 
251 depending on the applied dose (Fig. 3). 170 
 171 
5. Discussion 172 
Our findings showed, that prior blockade of 5-HT2C receptors was able to prevent the 173 
reduction in locomotor and explorative activity caused by CB1 receptor antagonist. Consistent 174 
with our results, similar exploration reducing effect of AM-251 have been found in the open 175 
field test [19]. Interestingly, we could not see a consistent effect of AM-251 on anxiety. This 176 
is in agreement with results showing that AM-251 had no consistent effects on anxiety in rats 177 
[20-23]. Considering the pooled safety results of human RIO (Rimonabant-In-Obesity) 178 
studies, rimonabant (an antagonist of CB1 receptors) has also caused anxiety in a relatively 179 
low percentage (5.6 %) of patients [1].  180 
Rearing behavior, when animals standing on both hind paws in a vertical upright posture, is 181 
definitely considered as locomotor and exploratory activity, but can also be used as an 182 
unstable indicator of anxiety, since both increase and decrease of this parameter have been 183 
shown to correlate with anxiety [24]. On the other hand, in behavioral studies in rats, increase 184 
or decline in locomotor activity have frequently been interpreted as psychomotor agitation 185 
and retardation, respectively [25, 26]. Based on this, decline in both rearing behavior and 186 
locomotor activity (CAE in the EPM test) as well as the lack of a significant anxiogenic-like 187 
effect in our study, suggest that blockade of CB1 receptors produces psychomotor retardation 188 
rather than a pronounced anxiety-like effect. Regarding the involvement of the eCB system in 189 
locomotor regulation in humans, chronic cannabis smokers showed reduced activation of 190 
cortical motor areas in finger sequencing task [27] and a decline in psychomotor function 191 
during abstinence [6]. Furthermore, CB1 receptor downregulation has been observed in 192 
cortical areas and in the basal ganglia in humans, but also in animals chronically exposed to 193 
cannabinoids [7, 8].  194 
Indeed, brain structures that participate in the regulation of movement, like basal ganglia and 195 
cortical areas, show high density of CB1 receptors [10]. In Δ9-tetrahydrocannabinol tolerant 196 
animals, rimonabant induced c-fos expression and decreased dopamine release in both the 197 
nucleus accumbens and the amygdala [28]. This effect is thought to be related to dysphoric 198 
consequences of cannabinoid withdrawal, such as psychomotor retardation [8]. Based on 199 
these findings, the cause of the decreased locomotor activity by AM-251 in our study might 200 
be the decline of CB1 receptor activity in movement regulating brain structures. 201 
Regarding the locomotor effect of selective 5-HT2C receptor antagonist, SB-242084 increased 202 
locomotor activity in the SI test in our study. The involvement of 5-HT2C receptors in 203 
movement regulation has been suggested by the abundant presence of 5-HT2C receptors in 204 
movement regulating brain structures, interestingly in the close proximity of CB1 receptors 205 
[9]. This is also supported by data from 5-HT2C receptor null mutant mice showing increased 206 
extracellular dopamine levels in the nucleus accumbens [29]. Also, 5-HT2C receptor agonists 207 
blocked, whereas antagonists facilitated the cocaine-induced increase in locomotor activity 208 
and dopamine signaling in the nucleus accumbens core [30-32]. According to these findings, 209 
increased locomotor activity by SB-242084 in our experiment might have occurred as a result 210 
of increased dopamine signaling in the nucleus accumbens region and presumably other 211 
regions involved in the regulation of locomotion.  212 
Elevated stress, increased serotonin levels and activation of Gq/11 protein coupled 5-HT2C 213 
receptors can be measured during SI and EPM tests in rodents [33]. In the same tests, 5-HT2C 214 
receptor blockade by SB-242084 treatment showed anxiolytic-like effect in our study, in 215 
agreement with previous findings [16, 34]. However, the effect of the consecutive 216 
administration of 5-HT2C and CB1 receptor antagonists on anxiety-regulation is not clear, 217 
because the influence of AM-251 on the SB-242084-induced anxiolytic-like effect seemed to 218 
depend on the given behavioral test. AM-251 markedly reduced the effects of SB-242084 in 219 
the SI test (number of social interactions), but had minimal or no effect on the OAT and OAE 220 
indices in the EPM test. In our study, we applied two different behavioral paradigm: in the SI 221 
test, the less avoidable stress is caused by an unfamiliar partner in the SI arena, while in the 222 
EPM test, the stress is the effect of the open space and high light that is avoidable in the 223 
closed arms. Our finding, that AM-251 modified the anxiolytic-like effect of SB-242084 224 
under less avoidable social stress conditions, have shown the sensitivity of eCB system in 225 
terms of the stress controllability. Based on these results, we presume that 5-HT2C and CB1 226 
receptor antagonists might cause an additive pharmacological effect, modifying anxiety-like 227 
behavior. 228 
At the same time, several data suggest the interaction between serotonin and CB1 receptors in 229 
rodents and humans [3, 35]. Burattini et al. have found that stimulation of 5-HT2 receptors 230 
evoked production of 2-arachidonoylglycerol, an endogenous agonist of the CB1 (and CB2 231 
receptors), and activated CB1 receptors in the nucleus accumbens core [36]. Furthermore, in 232 
CB1 knockout mice, diminished expression of 5-HT2C receptors has been observed in the 233 
nucleus accumbens [37], suggesting their strong interplay in this brain region. A clear 234 
interaction between CB1 and 5-HT2C receptors has also been reported in appetite regulation 235 
through the modulation of signaling in the nucleus accumbens, demonstrating that SB-242084 236 
pretreatment was able to prevent the hypophagic effect produced by the combination of 237 
oleamide (a cannabimimetic drug) and AM-251 [12]. Taken together, blockade of 5-HT2C 238 
receptors interferes with the influence of CB1 receptors in locomotor regulation, suggesting 239 
that serotonergic and cannabinoid systems are both involved in the regulation of this pathway. 240 
This effect is likely pharmacodynamics and not pharmacokinetic, because AM-251 and its 241 
structural analog rimonabant are metabolized through microsomal enzimes in vitro [38], but 242 
SB-242084 has not influenced the activity of P450 enzimes [39]. 243 
 244 
6. Conclusion 245 
The potential therapeutic use of compounds acting on the eCB system is still an intensively 246 
investigated area. Our results point to an interplay between 5-HT2C and CB1 receptors in 247 
regulating processes related to the locomotor activity and explorative behavior. Utilizing the 248 
advantageous effect of CB1 and 5-HT2C receptor antagonists, their combined application 249 
might comprise a promising new direction for the therapeutic application of drugs with CB1 250 
receptor blocking activity.  251 
 252 
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9. Figures and figure legends 391 
Fig. 1. Influence of SB-242084 (SB, 1 mg/kg, ip.), AM-251 (AM D5 and AM D10, 5 and 10 392 
mg/kg, ip.) and their combination on explorative behaviors and locomotor activity in social 393 
interaction test (A, B) and elevated plus maze test (C). Graphs show the time spent with 394 
rearing (A), the number of line crossings (B) and the number of closed arm entries (C). N=12-395 
16 for all groups. Columns represent mean ± S.E.M. * p < 0.05 and *** p < 0.001, significant 396 
results of Dunnett’s post hoc test compared to VEH+VEH group.   397 
Fig. 2. Effects of SB-242084 (1 mg/kg, ip.), AM-251 (5 mg/kg, ip.) and their combination on 398 
anxiety-like behaviors in the social interaction test. Graphs show the time (A) and the number 399 
(B) of total social interaction, and time (C) and number (D) of self-grooming. N=12-16 for all 400 
groups. Columns represent mean ± S.E.M. * p < 0.05, significant results of Dunnett’s post 401 
hoc test compared to VEH+VEH group.   402 
Fig. 3. Influence of SB-242084 (1 mg/kg, ip.), AM-251 (5 or 10 mg/kg, ip.) and their 403 
combination on anxiety-related behaviors in elevated plus maze test. Graphs show the 404 
absolute time and the percentage of the time spent in open arms (A and B, respectively), the 405 
number of open arm entries (C) and the percentage of the number of open arm entries (D). 406 
N=10-14 for all groups. Columns represent mean ± S.E.M. * p < 0.05, significant results of 407 
Dunnett’s post hoc test compared to VEH+VEH group.  408 
